Smart wearables firm Zepp Health's Q2 revenue rises on new product launches

Zepp Health expects Q3 2026 net revenues between $68 million and $73 million.

The company said improved product mix and demand will not be fully reflected in Q3 revenue due to supply and production cycles.

Zepp Health expects overall expense levels to decline as the pace of new product launches moderates.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell".

The average consensus recommendation for the phones & handheld devices peer group is "buy."

Wall Street's median 12-month price target for Zepp Health Corp is $61.83, about 1,274% above its September 1 closing price of $4.50.

• New product launches — The company said Q2 sales growth was mainly driven by launches of Active 3 Premium, Active Max and Cheetah models.